This study looked at people with a rare genetic form of heart‑related amyloidosis. It found that those who have two copies of the V122I mutation (homozygous) develop symptoms and serious heart problems about 8‑10 years earlier than those with just one copy (heterozygous). The research mainly describes disease timing and severity, not any new treatment or lifestyle tip.

Hereditary transthyretin (ATTRv) p.Val142Ile (V122I) mutation is the most common inherited cause of cardiac amyloidosis and little is known about the phenotype and outcome of the rare homozygotic genotype. This study aimed to compare phenotypic characteristics and outcomes between heterozygous and homozygous patients with ATTRv V122I amyloidosis. This monocentric, observational, retrospective study conducted at the French National Referral Centre for Cardiac Amyloidosis (Henri Mondor Hospital, Cr&#xe9;teil), described clinical, electrocardiographic, cardiac imaging features and prognostic data for patients with ATTRv V122I amyloidosis. Among 185 ATTRv V122I patients identified, 161 were heterozygous and 24 were homozygous. The homozygous frequency was 13%. Onset occured significantly earlier in the homozygotes compared to heterozygotes with earlier median age at diagnosis (67[63-71] years vs 76[70-79] years, <i>p</i>&#x2009;&lt;&#x2009;.001), age at first cardiac symptom (66[61-71] years vs 74[68-78] years, <i>p</i>&#x2009;&lt;&#x2009;.001) and age at first extracardiac symptom (59[52-70] years vs 69[62-75] years, <i>p</i>&#x2009;=&#x2009;.003). Homozygous ATTRv V122I was also associated with greater disease burden with earlier events (death, transplant or hospitalisation for acute heart failure) compared with heterozygotes (71[67-74] vs 78[76-79] years, <i>p</i>&#x2009;=&#x2009;.018). This rare, homozygous V122I cohort confirmed the earlier age of onset, death and cardiac events in this population.